Back to Search
Start Over
Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections
- Source :
- Repositório Institucional da UNIFESP, Universidade Federal de São Paulo (UNIFESP), instacron:UNIFESP
- Publication Year :
- 2010
-
Abstract
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Pan-American Association of Ophthalmology/Pan-American Ophthalmologic Foundation Deutsche Ophthalmologische Gesellschaft (DOG) Fehr Foundation, Marburg Purpose: To determine the incidence of rhegmatogenous retinal detachments (RD) after intravitreal injection in six high-volume centres.Methods: A consecutive, interventional, multicenter case series measured the incidence of RD in patients receiving intravitreal anti-VEGF. A total of 35 942 intravitreal anti-VEGF injections (the number of the injections determined by review of injection log books over a 3 year period) were performed under sterile conditions with the patient in a supine position. Injections were given 3.5-4.0 mm behind the limbus in a tunnelled fashion.Results: During 36 consecutive months, five RD were reported, between 2 and 6 days after the injection. of the affected eyes, four were myopic) 1.75 to) -5.5 dpt. the incidence rate of rhegmatogenous RD was 0.013% (5/35 942) per injection.Conclusions: the incidence of RD in our community setting was very low (1 per 7188 injections). All RD occurred during the early postoperative period. the risks of RD can be minimized by a careful injection technique. Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany Univ Marburg, Dept Ophthalmol, Marburg, Germany Avastin Data Base Bonn, Bonn, Germany Triemli Hosp, Dept Ophthalmol, Zurich, Switzerland Universidade Federal de São Paulo, Vis Inst IPEPO, São Paulo, Brazil Asklepios Clin, Dept Ophthalmol, Hamburg, Germany Eye Clin, Duisburg, Germany Universidade Federal de São Paulo, Vis Inst IPEPO, São Paulo, Brazil Web of Science
- Subjects :
- Male
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Supine position
Bevacizumab
Iatrogenic Disease
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
rhegmatogenous retinal detachments
Macular Edema
chemistry.chemical_compound
Macular Degeneration
Postoperative Complications
needle
Risk Factors
Ophthalmology
Ranibizumab
Retinal Vein Occlusion
medicine
Humans
In patient
Aged
Aged, 80 and over
business.industry
Incidence (epidemiology)
Incidence
Retinal Detachment
intravitreal injection
Antibodies, Monoclonal
Retinal
General Medicine
iatrogenic damage
Middle Aged
adverse events
Choroidal Neovascularization
Surgery
Multicenter study
chemistry
Intravitreal Injections
Community setting
ora serrata
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 17553768
- Volume :
- 89
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Acta ophthalmologica
- Accession number :
- edsair.doi.dedup.....df9fc63848d029577e322a31e3a48e21